Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · IEX Real-Time Price · USD
10.26
+0.16 (1.58%)
Mar 28, 2024, 1:18 PM EDT - Market open

Vir Biotechnology Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year 2023202220212020201920182017
Cash & Equivalents
254.84861.31356.41444.57115.5258.36187.92
Short-Term Investments
1,2811,553360.33300.29274.150.850
Cash & Cash Equivalents
1,5362,415716.74744.85389.62109.2187.92
Cash Growth
-36.40%236.90%-3.77%91.18%256.78%-41.89%-
Receivables
00773.080000
Other Current Assets
52.55104.367327.5113.388.584.43
Total Current Assets
1,5882,5191,563772.37403117.78192.35
Property, Plant & Equipment
167.2188.17130.0579.8916.3112.295.14
Long-Term Investments
111.7230.58208.396.9231.5911
Goodwill and Intangibles
39.549.6950.2250.7652.6353.8552.82
Other Long-Term Assets
12.4114.572.788.838.556.670.26
Total Long-Term Assets
330.83283.01391.45146.4109.0873.8159.22
Total Assets
1,9192,8021,954918.76512.07191.6251.57
Accounts Payable
6.336.426.525.085.886.474.9
Deferred Revenue
66.3868.72102.0210.2718.8515.320.89
Other Current Liabilities
102.69435.88232.783.7234.4718.116.65
Total Current Liabilities
175.41511.03341.2499.0659.2139.9112.44
Long-Term Debt
111.67123.84133.5666.56000
Other Long-Term Liabilities
41.7489.2647.6236.2928.9221.7315.52
Total Long-Term Liabilities
153.42213.1181.18102.8528.9221.7315.52
Total Liabilities
328.82724.13522.42201.9188.1361.6427.96
Total Debt
111.67123.84133.5666.56000
Debt Growth
-9.82%-7.28%100.67%----
Retained Earnings
-237.82377.24-138.6-667.18-368.52-193.84-77.95
Comprehensive Income
-0.82-9.12-1.1-1.28-0.6-0.010
Shareholders' Equity
1,5902,0781,432716.85423.94-179.18-68.92
Net Cash / Debt
1,4242,291583.18678.3389.62109.2187.92
Net Cash / Debt Growth
-37.84%292.83%-14.02%74.09%256.78%-41.89%-
Net Cash Per Share
10.6216.994.375.6912.8414.2487.31
Working Capital
1,4132,0081,222673.3343.7977.88179.91
Book Value Per Share
11.8615.6711.026.0213.97-23.37-32.02
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).